Related Experiment Videos
Altered response to ibutilide in a heart failure model
S S Chugh1, S B Johnson, D L Packer
1Division of Cardiovascular Disease, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN, USA. chughs@ohsu.edu
Cardiovascular Research
|December 21, 2000
Summary
Congestive heart failure (CHF) alters how anti-arrhythmic drugs like ibutilide work, increasing action potential duration and dispersion. These findings highlight potential risks of using such drugs in CHF patients due to electrical remodeling.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Anti-arrhythmic drugs are widely used, but their effects in congestive heart failure (CHF) are not well understood.
- Left ventricular dysfunction in CHF may alter drug responses.
Purpose of the Study:
- To investigate the electrophysiologic effects of type III anti-arrhythmic drugs in a canine model of pacing-induced dilated cardiomyopathy.
- To examine how left ventricular dysfunction impacts the action of ibutilide.
Main Methods:
- Evaluated ibutilide's effects on action potential duration at 90% (APD(90)) in canine models with and without pacing-induced dilated cardiomyopathy.
- Recorded monophasic action potentials from ventricular endocardium/epicardium after administering three doses of ibutilide.
Main Results:
- Ibutilide caused significantly greater APD(90) prolongation in CHF animals compared to controls at a low dose (0.01 mg/kg).
- Increased dispersion of ventricular APD(90) was observed in CHF animals but not in controls.
- A trend towards increased non-sustained polymorphic ventricular tachycardia was noted in CHF.
Conclusions:
- The electrophysiologic actions of ibutilide are significantly altered in the presence of congestive heart failure.
- These alterations may be attributed to myocardial electrical remodeling in CHF, affecting drug efficacy and safety.